Avacincaptad pegol
Medication
From Wikipedia, the free encyclopedia
Avacincaptad pegol, sold under the brand name Izervay, is a medication used for the treatment of age-related macular degeneration.[1] Avacincaptad pegol is a complement inhibitor.[1]
Trade namesIzervay
Other namesZimura
| Clinical data | |
|---|---|
| Trade names | Izervay |
| Other names | Zimura |
| License data | |
| Routes of administration | Intravitreal |
| Drug class | Complement inhibitor |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C395H453F21N142Na39O262P39 |
| Molar mass | 13885.245 g·mol−1 |
Avacincaptad pegol was approved for medical use in the United States in August 2023.[2][3][4]
Medical uses
Avacincaptad pegol is indicated for the treatment of geographic atrophy secondary to age-related macular degeneration.[5]
Society and culture
Avacincaptad pegol is the international nonproprietary name.[6]
